Clin2
NCT05717153Possibly a fitRecruiting

Test drugs through the tumor to study brain tumor metabolism

Diffuse GliomaMalignant Glioma

Treatments studied

Part of Cancer clinical trials.

This early-phase study tests two drugs (DFMO and AMXT 1501) given directly into the tumor to see how they affect tumor biology and metabolism. Researchers may learn whether this approach could be safer and helpful for people with diffuse or high-grade glioma.

Summary written for real people, not researchers, by Clin2.

Phase
Early Phase 1
Enrollment
18 people
Ages
18 years and older
Study type
Interventional

Who can take part

  • You are 18 years or older
  • You have a diffuse or high-grade brain tumor diagnosis based on scan and/or past diagnosis
  • Your neurosurgeon plans a biopsy or partial removal because of where the tumor is
  • You can stay in the hospital at Mayo Clinic for extra days for monitoring and sampling
  • Your blood counts and liver/kidney tests are in acceptable ranges, and you can have MRI scans
  • You can take oral study medicine (swallow tablets) and you do not have a drug allergy to DFMO or AMXT 1501

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT07468136Recruiting· Phase 1/Phase 2
Retifanlimab with or without DFMO for progressive high-grade gliomas

This study tests a combination of two drugs—retifanlimab (an immunotherapy that helps your immune system fight cancer) and DFMO (a medicine that may stop tumor growth)—in people with high-grade brain tumors that are growing. Participants will receive these treatments before and after their planned surgery.

Rochester, Minnesota
NCT07025226Recruiting· Early Phase 1
Combination drugs and vaccine for glioma with remaining tumor

This trial tests a combination of several drugs and a vaccine to see if they can help treat glioma that has not gone away with previous treatment. It is for people whose tumors have certain gene changes and who still have some tumor remaining after standard therapy.

Rochester, Minnesota
NCT07301268Recruiting· Phase 2
GI-102 with or without pembrolizumab before brain surgery

This trial is testing a new drug called GI-102, given alone or with pembrolizumab, before surgery for a type of brain tumor called glioblastoma or grade 4 astrocytoma. The goal is to see if these drugs can help shrink the tumor before it's removed.

Rochester, Minnesota
NCT07461948Recruiting· Phase 3
Advanced imaging study for glioblastoma patients

This trial uses special MRI scans and a contrast agent to look at the immune environment of glioblastoma tumors. It may help doctors learn more about how the tumor responds to treatment.

Los Angeles, California
NCT07627334Recruiting
Personalized drug testing for newly diagnosed brain tumors

This trial tests whether customized drug screening on your tumor cells can help doctors choose the best treatment for you. Your tumor cells will be grown in the lab and tested against different drugs to find what works best, combined with short-course radiation therapy.

Vienna, State of Vienna
NCT06804655Not yet recruiting· Phase 2
Personalized drug testing for stubborn brain tumors

This study tests a new way to choose treatment for people with brain tumors that have not responded to standard therapies. Your tumor sample is analyzed in the lab to find which drugs might work best for you, and then you receive a personalized treatment plan.

Basel, Basel-Landschaft

Hear when a new Diffuse Glioma trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.